EWP
RARE icon

Elevation Wealth Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Elevation Wealth Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-163
Closed -$3.75K – 1122
2025
Q4 		$3.75K Buy
+163
New +$5.36K ﹤0.01% 684

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Elevation Wealth Partners's RARE Position: Q1 2026 in Review

Elevation Wealth Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 163 shares — an estimated $3.75K sold.

Elevation Wealth Partners first reported a position in RARE in Q4 2025 and held it in 1 quarter. The position peaked at $3.75K in Q4 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Elevation Wealth Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Elevation Wealth Partners sold 163 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.75K.
  • Elevation Wealth Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and held it in 1 quarter.
  • Elevation Wealth Partners's Ultragenyx Pharmaceutical position peaked at $3.75K in Q4 2025.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Elevation Wealth Partners's 13F filing for Q1 2026, filed 14 Apr 2026.